Brought to you by 
Fate Therapeutics, Inc.
https://fatetherapeutics.com/
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Fate Therapeutics, Inc.
Tech Transfer Roundup: Tonix Inks Trio Of COVID-19-Focused Deals
New York biotech is partnering with researchers at Columbia, Kansas State and Southern Research to address the pandemic.
Finance Watch: Four Offerings In One Week As Biopharma Keeps Its IPO Market Lead
Lantern, Avidity, Generation Bio and Vaxcyte launched initial public offerings during the second week of June as biopharma continues to intrigue IPO investors. Also, Blackstone invested $350m in Reata's bardoxolone and Checkmate’s $85m series C led recent VC deals.
J&J Spots Potential Of Fate’s Stem Cells, Signs Cancer Deal Worth Up To $3bn
Investment from Janssen helps to validate the platform developed by the San Diego-based company.
Coronavirus Update: Novartis Targets COVID-19 Cytokine Storm With Jakavi
Novartis's Jakavi joins the likes of Roche's Actemra in targeting the life-threatening immune reaction which is killing acutely ill COVID-19 patients.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
-
- Tfinity Therapeutics, Inc.